USD10
EXEL Shares
About ExelixisExelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
USD10
EXEL Shares
About ExelixisExelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$14.06B
OPEN PRICE
$55.00
LOW (1Y)
$33.76
HIGH (1Y)
$57.57
LOW (24H)
$54.75
HIGH (24H)
$56.10
VOLUME (24H)
$2.56M
25.83%
Price history
Time | Price | Change |
|---|---|---|
Today | $55.00 | |
1 Day | $55.20 | |
1 Week | $56.40 | |
1 Month | $52.12 | |
1 Year | $44.26 |
Past performance is not a reliable indicator of future results.
Discover more
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.